Ipca Laboratories Limited

Established in Mumbai, India, in 1949, Ipca Laboratories Limited operates as a pharmaceutical enterprise focused on developing and commercializing both active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. Its API offerings span critical therapeutic areas, including anti-hypertensive, anti-malarial, diuretic, DMARD (disease-modifying anti-rheumatic drugs), and anthelmintic applications. The company provides an extensive portfolio of generic and branded formulations tailored for a broad spectrum of medical conditions. These therapeutic segments include allergies, oncology (cancer drugs), anti-arthritic conditions, epilepsy, hypertension, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, urology, psychiatry, respiratory ailments, orthopedics, oral anti-diabetes treatments, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppression, hepatoprotection, helminthic infections, fever, and emollients/protectives. In addition to its significant presence within India, Ipca Laboratories also exports its diverse range of products globally.

CEO: Pranay Premchand Godha - https://www.ipca.com